Jnj-101556143
Phase 1
Johnson & JohnsonJnj-101556143 is one of 29 therapeutic programs targeting Metastatic Castration-resistant Prostate Neoplasms. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
28
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
31 competitors in Prostatic Neoplasms
#DrugCompanyPhaseTrials
1Erleada
Johnson & JohnsonPhase 3
Zytiga
Johnson & JohnsonPhase 3
Verzenio
Eli LillyPhase 3
Xtandi
AstellasPhase 3
Keytruda
Merck & Co.Phase 3
Rayos
RRoxane Laboratories
Phase 3
Casodex
IIstituto Clinico Humanitas
Phase 3
Androgen Deprivation Therapy
Johnson & JohnsonPhase 3
Prednisone or Prednisolone
Johnson & JohnsonPhase 3
Gnrh
MMassachusetts General Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostatic Neoplasms1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Jnj-101556143. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company